Curine inhibits eosinophil activation and airway hyper-responsiveness in a mouse model of allergic asthma

Toxicology and Applied Pharmacology

Volumn 273, Issue 1, 2013, Pages 19-26

  Ribeiro Filho, Jaime ^a,c   Calheiros, Andrea Surrage ^a   Vieira de Abreu, Adriana ^a   de Carvalho, Katharinne Ingrid Moraes ^a   da Silva Mendes, Diego ^a   Melo, Christianne Bandeira ^b   Martins, Marco Aurélio ^a   da Silva Dias, Celidarque ^c   Piuvezam, Márcia Regina ^c   Bozza, Patrícia T ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Airway hyper responsiveness; Allergy; Calcium; Curine; Eosinophil activation; Toxicity

Indexed keywords

BEBEERINE; CALCIUM; DEXAMETHASONE; EOTAXIN; INTERLEUKIN 13; METHACHOLINE; OVALBUMIN; VERAPAMIL;

ALLERGIC ASTHMA; ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; CALCIUM BLOOD LEVEL; CELL ACTIVATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG PURIFICATION; DRUG STRUCTURE; EOSINOPHIL; EX VIVO STUDY; HISTOLOGY; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; RESPIRATORY TRACT ALLERGY; SINGLE DRUG DOSE; THERAPY EFFECT;

AIRWAY HYPER-RESPONSIVENESS; ALLERGY; CALCIUM; CURINE; EOSINOPHIL ACTIVATION; TOXICITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; CALCIUM; DISEASE MODELS, ANIMAL; EOSINOPHILS; INFLAMMATION; INTERLEUKIN-13; ISOQUINOLINES; MALE; MENISPERMACEAE; MICE; MICE, INBRED BALB C; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OVALBUMIN; RATS; RATS, WISTAR; VERAPAMIL;

EID: 84884727065     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.08.015     Document Type: Article

References (43)

1. Barnes P.J. How corticosteroids control inflammation. Br. J. Pharmacol. 2006, 148:245-254.
2. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008, 8:183-192.
3. Barnes P.J. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 2011, 163:29-43.
4. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-1917.
5. Barnes P.J., Greening A.P., Crompton G.K. Glucocorticoid resistance in asthma. Am. J. Respir. Crit. Care Med. 1995, 152:125-140.
6. Bezerra-Santos C.R., Peçanha L.M.T., Piuvezam M.R. Cissampelos sympodialis Eichl. (Menispermaceae) inhibits anaphylactic shock reaction in murine allergic model. Braz. J. Pharmacogn. 2005, 15:287-291.
7. Bezerra-Santos C.R., Vieira-de-Abreu A., Barbosa-Filho J.M., Bandeira-Melo C., Piuvezam M.R., Bozza P.T. Anti-allergic properties of Cissampelos sympodialis and its isolated alkaloid warifteine. Int. Immunopharmacol. 2006, 6:1152-1160.
8. Bezerra-Santos C.R., Vieira-de-Abreu A., Vieira G.C., Ribeiro-Filho J., Barbosa-Filho J.M., Pires A.L., Martins M.A., Souza H.S., Bandeira-Melo C., Bozza P.T., Piuvezam M.R. Effectiveness of Cissampelos sympodialis and its isolated alkaloid warifteine in airway hyperreactivity and lung remodeling in a mouse model of asthma. Int. Immunopharmacol. 2012, 13:148-155.
9. Bloemen K., Verstraelen S., Van-Den-Heuvel S., Witters H., Nelissen I., Schoeters G. The allergic cascade: review of the most important molecules in the asthmatic lung. Immunol. Lett. 2007, 113:6-18.
10. Boswell-Smith V., Cazzola M., Page C.P. Are phosphodiesterase-4 inhibitors just more theophylline?. J. Allergy Clin. Immunol. 2006, 117:1237-1243.
11. Bozza P.T., Yu W., Penrose J.F., Morgan E.S., Dvorak A.M., Weller P.F. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J. Exp. Med. 1997, 186:909-920.
12. Bozza P.T., Magalhães K.G., Weller P.F. Leukocyte lipid bodies - biogenesis and functions in inflammation. Biochem. Biophys. Acta 2009, 1791(6):540-551.
13. Chatila T.A. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol. Med. 2004, 10:493-499.
14. Costa H.F., Bezerra-Santos C.R., Barbosa-Filho J.M., Martins M.A., Piuvezam M.R. Warifteine, a bisbenzylisoquinoline alkaloid, decreases immediate allergic and thermal hyperalgesic reactions in sensitized animals. Int. Immunopharmacol. 2008, 8:519-525.
15. Dias C.S., Barbosa-Filho J.M., Lemos V.S., Cortes S.F. Mechanisms involved in the vasodilator effect of curine in rat resistance arteries. Planta Med. 2002, 68:1049-1051.
16. Edwards A.M., Howell J.B. The chromones: history, chemistry and clinical development. A tribute to the work of Dr R. E. C. Altounyan. Clin. Exp. Allergy 2000, 30:756-774.
17. Edwards M.R., Bartlett N.W., Clarke D., Birrell M., Belvisi M., Johnston S.L. Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol. Ther. 2009, 121:1-13.
18. Faqi A. A Comprehensive Guide to Toxicology in Preclinical Drug Development 2012, Academic Press, New York. First ed.
19. 2+ and other actions of verapamil in guinea-pig isolated trachealis. Br. J. Pharmacol. 1984, 81:499-507.
20. Gleich G.J. Mechanisms of eosinophil-associated inflammation. J. Allergy Clin. Immunol. 2000, 105:651-663.
21. Harrison T.W., Oborne J., Newton S., Tattersfield A.E. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004, 363:271-275.
22. Holgate S.T., Polosa R. Treatment strategies for allergy and asthma. Nat. Rev. Immunol. 2008, 8:116-124.
23. Ivancsó I., Böcskei R., Müller V., Tamási L. Extrafine inhaled corticosteroid therapy in the control of asthma. J. Asthma Allergy 2013, 6:69-80.
24. Khakzad M.R., Mirsadraee M., Mohammadpour A., Ghafarzadegan K., Hadi R., Saghari M., Meshkat M. Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. Pulm. Pharmacol. Ther. 2012, 25:163-168.
25. Kuperman D.A., Lewis C.C., Woodruff P.G., Rodriguez M.W., Yang Y.H., Dolganov G.M., Fahy J.V., Erle D.J. Dissecting asthma using focused transgenic modeling and functional genomics. J. Allergy Clin. Immunol. 2005, 116:305-311.
26. Lauzon A.M., Bates H.T., Donovan G., Tawhai M., Sneid J., Sanderson M.J. A multi-scale approach to airway hyperresponsiveness: from molecule to organ. Front. Physiol. 2012, 3:1-25.
27. Lloyd C.M., Gonzalo J.A., Nguyen T., Delaney T., Tian J., Oettgen H., Coyle A.J., Gutierrez-Ramos J.C. Resolution of bronchial hyperresponsiveness and pulmonary inflammation is associated with IL-3 and tissue leukocyte apoptosis. J. Immunol. 2001, 166:2033-2204.
28. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 2005, 5:472-484.
29. Mambu L., Martin M.T., Razafimahefa D., Ramanitrahasimbola D., Rasoanaivo P., Frappier F. Spectral characterization and antiplasmodial activity of bisbenzylisoquinolines from Isolona ghesquiereina. Planta Med. 2000, 66:537-540.
30. 2+ transients in A7r5 cells. Eur. J. Pharmacol. 2011, 669:100-107.
31. 4 synthesis by eosinophils during allergic inflammation: synergistic in vivo role of endogenous eotaxin. J. Immunol. 2006, 176:1326-1330.
32. Moynihan B.J., Tolloczko B., Bassam S.E., Ferraro P., Michoud M., Martin J.G., Laberge S. IFN-γ, IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13. Respir. Res. 2008, 9(1):84.
33. 2-type immune responses initiated and amplified. Nat. Rev. Immunol. 2010, 10:225-235.
34. Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr. Opin. Pulm. Med. 2007, 13:24-30.
35. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 2005, 353:1711-1723.
36. Rothenberg M.E., Robert-Ownbey T., Mehlhop P.D., Loiselle P.M., Van de Rijn M., Bonventre J.V., Oettgen H.C., Leder P., Luster A.D. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol. Med. 1996, 2(3):334-348.
37. Schacke H., Schottelius A., Docke W.D., Strehlke P., Jaroch S., Schmees N., Rehwinkel H., Hennekes H., Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:227-232.
38. Seow W.K., Li S.T.Y., Thong Y.H. Inhibitory effect of tetrandrine on human neutrophil and monocyte adherence. Immunol. Lett. 1986, 13:83-88.
39. Szefler S.J. Advancing asthma care: the glass is only half full. J. Allergy Clin. Immunol. 2011, 128(3):485-494.
40. Teh B.S., Seow W.K., Li S.Y., Thong Y.H. Inhibition of prostaglandin and leukotriene generation by the plant alkaloids tetrandrine and berbamine. Int. J. Immunopharmacol. 1990, 12:321-326.
41. Truyen E., Coteur L., Dilissen E., Overbergh L., Dupont L.J., Ceuppens J.L., Bullens D.M. Evaluation of airway inflammation by quantitative TH1/TH2 cytokine mRNA measurement in sputum of asthma patients. Thorax 2006, 61:202-208.
42. 4 synthesis within eosinophils. Am. J. Respir. Cell Mol. Biol. 2005, 33:254-261.
43. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., Donaldson D.D. Interleukin-13: central mediator of allergic asthma. Science 1998, 282:2258-2261.